Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,824 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Fas and Fas ligand: lpr and gld mutations.
Nagata S, Suda T. Nagata S, et al. Immunol Today. 1995 Jan;16(1):39-43. doi: 10.1016/0167-5699(95)80069-7. Immunol Today. 1995. PMID: 7533498 Review.
Here, Shigekazu Nagata and Takashi Suda summarize current knowledge of Fas and FasL, and discuss the physiological role of the Fas system in T-cell development, cytotoxicity and cytotoxic T lymphocyte (CTL)-mediated autoimmune disease....
Here, Shigekazu Nagata and Takashi Suda summarize current knowledge of Fas and FasL, and discuss the physiological role of the Fas sy …
Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis.
Kuwano K, Hagimoto N, Kawasaki M, Yatomi T, Nakamura N, Nagata S, Suda T, Kunitake R, Maeyama T, Miyazaki H, Hara N. Kuwano K, et al. J Clin Invest. 1999 Jul;104(1):13-9. doi: 10.1172/JCI5628. J Clin Invest. 1999. PMID: 10393694 Free PMC article.
Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H. Hashimoto W, et al. J Immunol. 1999 Jul 15;163(2):583-9. J Immunol. 1999. PMID: 10395644
Levels of soluble Fas ligand in myocarditis.
Toyozaki T, Hiroe M, Tanaka M, Nagata S, Ohwada H, Marumo F. Toyozaki T, et al. Am J Cardiol. 1998 Jul 15;82(2):246-8. doi: 10.1016/s0002-9149(98)00300-2. Am J Cardiol. 1998. PMID: 9678301
Fas-induced apoptosis.
Nagata S. Nagata S. Intern Med. 1998 Feb;37(2):179-81. doi: 10.2169/internalmedicine.37.179. Intern Med. 1998. PMID: 9550601 Review. No abstract available.
Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis.
Hashimoto H, Tanaka M, Suda T, Tomita T, Hayashida K, Takeuchi E, Kaneko M, Takano H, Nagata S, Ochi T. Hashimoto H, et al. Arthritis Rheum. 1998 Apr;41(4):657-62. doi: 10.1002/1529-0131(199804)41:4<657::AID-ART12>3.0.CO;2-N. Arthritis Rheum. 1998. PMID: 9550474
Apoptosis mediated by the Fas system.
Nagata S. Nagata S. Prog Mol Subcell Biol. 1996;16:87-103. doi: 10.1007/978-3-642-79850-4_6. Prog Mol Subcell Biol. 1996. PMID: 8822794 Review.
The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity.
Shudo K, Kinoshita K, Imamura R, Fan H, Hasumoto K, Tanaka M, Nagata S, Suda T. Shudo K, et al. Eur J Immunol. 2001 Aug;31(8):2504-11. doi: 10.1002/1521-4141(200108)31:8<2504::aid-immu2504>;2-c. Eur J Immunol. 2001. PMID: 11500835
Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset Type I diabetes mellitus.
Moriwaki M, Itoh N, Miyagawa J, Yamamoto K, Imagawa A, Yamagata K, Iwahashi H, Nakajima H, Namba M, Nagata S, Hanafusa T, Matsuzawa Y. Moriwaki M, et al. Diabetologia. 1999 Nov;42(11):1332-40. doi: 10.1007/s001250051446. Diabetologia. 1999. PMID: 10550417
Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice.
Itoh N, Imagawa A, Hanafusa T, Waguri M, Yamamoto K, Iwahashi H, Moriwaki M, Nakajima H, Miyagawa J, Namba M, Makino S, Nagata S, Kono N, Matsuzawa Y. Itoh N, et al. J Exp Med. 1997 Aug 18;186(4):613-8. doi: 10.1084/jem.186.4.613. J Exp Med. 1997. PMID: 9254659 Free PMC article.
1,824 results
Jump to page